RGNX Logo

REGENXBIO Inc. (RGNX) 

NASDAQ
Market Cap
$462.6M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
695 of 776
Rank in Industry
379 of 433

Largest Insider Buys in Sector

RGNX Stock Price History Chart

RGNX Stock Performance

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is …

Insider Activity of REGENXBIO Inc.

Over the last 12 months, insiders at REGENXBIO Inc. have bought $0 and sold $4.52M worth of REGENXBIO Inc. stock.

On average, over the past 5 years, insiders at REGENXBIO Inc. have bought $0 and sold $6.42M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 175,000 shares for transaction amount of $3.85M was made by Flynn James E (10 percent owner) on 2015‑09‑22.

List of Insider Buy and Sell Transactions, REGENXBIO Inc.

2024-10-01Saledirector
10,000
0.0191%
$10.11$101,052-6.37%
2024-09-03Saledirector
10,000
0.0206%
$11.56$115,588-7.50%
2024-08-01SaleChief Executive Officer
100
0.0002%
$15.00$1,500-13.75%
2024-08-01Saledirector
10,100
0.0208%
$13.51$136,454-13.75%
2024-07-29SaleChief Executive Officer
9,648
0.0205%
$15.04$145,106-19.55%
2024-07-29Saledirector
11,000
0.0234%
$15.04$165,495-19.55%
2024-07-25Saledirector
15,369
0.0303%
$13.96$214,501-19.15%
2024-07-24Saledirector
12,221
0.0251%
$13.78$168,4330.00%
2024-07-17Saledirector
2,210
0.0047%
$13.77$30,440-12.09%
2024-07-16Saledirector
200
0.0005%
$13.76$2,752-13.86%
2024-07-01Saledirector
10,000
0.0199%
$11.27$112,6910.00%
2024-05-14SalePresident and CEO
15,000
0.0305%
$15.81$237,222-22.86%
2024-04-15SalePresident and CEO
15,000
0.0309%
$18.19$272,871-29.88%
2024-03-14SalePresident and CEO
15,000
0.03%
$21.86$327,942-39.22%
2024-03-05SaleChief Medical Officer
12,878
0.0328%
$28.36$365,220-44.60%
2024-02-14SalePresident and CEO
15,000
0.0329%
$16.76$251,349-14.59%
2024-01-16SalePresident and CEO
45,000
0.1017%
$15.18$682,992-7.87%
2024-01-03SaleChief Medical Officer
17,237
0.0398%
$17.39$299,789-16.59%
2023-12-19SalePresident and CEO
45,000
0.1027%
$19.68$885,825-26.69%
2023-01-03SaleChief Medical Officer
3,138
0.0072%
$22.17$69,559-14.17%

Insider Historical Profitability

<0.0001%
Flynn James E10 percent owner
1256542
2.5424%
$9.3610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$160.12M15.437.6M-7.41%-$12.82M<0.01
The Vanguard Group$102.76M9.94.88M+9.82%+$9.19M<0.01
Redmile Group$95.9M9.244.55M+21.03%+$16.66M0.98
JPMorgan Chase$78.43M7.563.72M-5.51%-$4.57M0.01
State Street$65.79M6.343.12M+18.68%+$10.35M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.